Edesa Biotech ( ($EDSA) ) has issued an update. Edesa Biotech, Inc. has partnered with H.C. Wainwright & Co., LLC to periodically sell its common shares on the market, a
Edesa Biotech ( ($EDSA) ) has issued an update. Edesa Biotech, Inc. has partnered with H.C. Wainwright & Co., LLC to periodically sell its common shares on the market, a
Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Edesa Biotech (EDSA – Research Report). The associated price target remains the same with $21.00. Vernon Bernardino has
Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its third-quarter financials for 2024, revealing a slight decrease in operating expenses and a strategic
Edesa’s Chief Financial Officer Stephen Lemieux reported that financial results for the three and nine months ended June 30, 2024 were in line with management’s expectations. “Our fiscal quarter and
סטיבן למיו, קצין הכספים של Edesa, אמר שתוצאות הכספים לשלושה ולתשעה חודשים שהסתיימו ב-30 ביוני 2024, התאימו למה שהנהלת Edesa ציפתה. הוא הסביר שהתוצאות לרבעון ולתקופה של תשעה חודשים מראות